Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Generic Fulvestrant Receives a Positive Opinion from the EMA CHMP

Fulvestrant Mylan is a generic of Faslodex, which has been authorised in the EU since 2004
14 Nov 2017
Breast cancer;  Anticancer agents & Biologic therapy

On 9 November 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product Fulvestrant Mylan, intended for the treatment of locally advanced or metastatic breast cancer.

The applicant for this medicinal product is Mylan S.A.S.

Fulvestrant Mylan will be available as a 250-mg solution for injection. The active substance of Fulvestrant Mylan is fulvestrant, an anti-oestrogen which attaches to the receptors for oestrogen on the surface of cells, thereby blocking the effects of the hormone and causing the number of oestrogen receptors to fall (ATC code: L02BA03). As a result, the tumour cells are not stimulated to grow by oestrogen and the growth of the tumour is reduced.

Fulvestrant Mylan is a generic of Faslodex, which has been authorised in the EU since 10 March 2004.

Studies have demonstrated the satisfactory quality of Fulvestrant Mylan. Since Fulvestrant Mylan is of the same type of solution, contains the same concentration of the active substance and has the same excipients in similar amounts as the medicinal product currently approved, a bioequivalence study versus the reference product Faslodex was not required.

The full indication is:

Fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:

  • not previously treated with endocrine therapy, or
  • with disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on anti-oestrogen therapy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion. 

Last update: 14 Nov 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.